Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iSCLife X (also known as D759389) is an allogeneic umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy developed by Sclnow Biotechnology (SCLnow) specifically for anti-aging and tissue restoration applications. The product utilizes pluripotent stem cells derived from neonatal umbilical cord tissue, which are stored in cryopreservant at -196°C in liquid nitrogen. The therapy works through mechanisms of migration tropism and pluripotency to activate dormant stem cell populations throughout the body and replace degenerated or aging cells. By restoring tissue and organ function and improving cellular communication that typically deteriorates with age, the treatment aims to enhance tissue activity and tolerance. It is administered as an intravenous drip preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iSCLife X.